Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05872685
Other study ID # IIT20230020C-R1
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date December 24, 2023
Est. completion date April 30, 2029

Study information

Verified date January 2024
Source First Affiliated Hospital of Zhejiang University
Contact Jiren Yu
Phone +86-0571-87236147
Email yujr0909@zju.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase II study is a prospective, multi-center, double-blinded, and randomized trial to compare the efficacy and safety of perioperative SOX plus serplulimab with SOX plus placebo for locally advanced gastric adenocarcinoma with proficient mismatch repair


Recruitment information / eligibility

Status Recruiting
Enrollment 314
Est. completion date April 30, 2029
Est. primary completion date April 30, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: 1. Voluntary participation in the clinical study; fully understands and is informed of the study and has signed the Informed Consent Form (ICF). 2. The gender is not limited. Age: = 18 years and = 80 years old. 3. Gastric or esophagogastric junction adenocarcinoma confirmed by pathology, and proficient mismatch repair confirmed by immunohistochemistry. 4. Clinical stage at presentation: cT2-T4b, N+/-, M0 as determined by AJCC staging system, 8th edition.The definition of metastatic lymph nodes: a lymph node must be = 10mm in short axis when assessed by CT scan (CT scan slice thickness recommended to be no greater than 5 mm) according to the guideline of Response Evaluation Criteria in Solid Tumours (RECIST version 1.1) 5. Participants with a performance status of 0 ~ 1 on the Eastern Cooperative Oncology Group (ECOG) within 7 days before the first dose of study treatment. 6. Life expectancy = 6 months. 7. Agreement of providing pretreatment endoscopic biopsies specimens and surgical specimens for biomarker analysis, as well as the peripheral blood, feces and urine sample. 8. The functions of the vital organs meet requirements as follow (within 14 days before the first dose of study treatment, participant has not received treatment of recombinant human thrombopoietin or granulocyte stimulating factor): 8.1 Hematological function: White blood cell count (WBC): 3.5 × 10 ^ 9 / L ~12.0 × 10 ^ 9 / L; Absolute neutrophil count (ANC) = 1.5 × 10 ^ 9 / L; Platelet count (PLT) = 100 × 10 ^ 9 / L; Hemoglobin (Hb) = 90 g / L. 8.2 Hepatic function: Total bilirubin (TBIL) = 1.5 × ULN (upper limit of normal); Aspartate aminotransferase (AST) = 2.5 × ULN; Alanine aminotransferase (ALT) = 2.5 × ULN; Albumin (ALB) = 30 g / L. 8.3 Renal function: Creatinine (Cr) = 1.5 × ULN, or creatinine clearance = 60 ml / min for those with creatinine level > 1.5 × ULN. 8.4 Coagulation function: International normalized ratio (INR) = 1.5; Prothrombin time (PT) and activated partial thromboplastin time (APTT) = 1.5 × ULN. 9. Female of childbearing age must meet requirements: urine or serum pregnancy test must be negative within 7 days before the first dose of study treatment, and she must agree to use adequate contraception methods or keep abstinence (starting with the ICF is signed through 120 days after the last dose of serplulimab, or 180 days after the last dose of chemotherapy, whichever is longer, and should not be breastfeeding. 10. For the male participants must meet requirements: agree to use adequate contraception methods or keep abstinence (starting with the ICF is signed through 120 days after the last dose of serplulimab, or 180 days after the last dose of chemotherapy, whichever is longer). Exclusion Criteria: 1. HER2-positive, EBER-positive or dMMR. 2. Prior systemic therapy for treatment of gastric cancer (surgery, chemotherapy, radiotherapy, targeted therapy or immunotherapy). 3. Previous or concurrent have other active malignant tumors within the past 5 years (except for basal cell or squamous cell carcinoma of the skin, superficial bladder cancer, prostate cancer or cervical cancer or breast cancer in situ that has undergone curative therapy). 4. Participants with gastric outlet obstruction, or unable for oral take, or severe gastrointestinal bleeding. 5. Myocardial infarction within 6 months before the first dose of study treatment, uncontrolled angina, arrhythmia which need medical intervention (including but not limited to cardiac pacemaker), congestive heart failure (New York Heart Association (NYHA) class III or IV). 6. Existence of chronic diarrhea (watery diarrhea: = 5 times per day). 7. Participants with active infection within 14 days before the first dose of study treatment which need medical intervention. 8. Participants with active tuberculosis. 9. Previous or concurrent diagnosed with interstitial lung disease by imaging or symptoms. 10. Any of the following test is positive: Human Immunodeficiency Virus (HIV) antibody, Hepatitis B surface Antigen (HBsAg), or Hepatitis C Virus (HCV) antibody. 11. Participants who need long-term systemic steroid therapy (> 10 mg/d prednisone equivalent) or any other form of immunosuppressive therapy within 14 days before the first dose of study treatment or during the study period. 12. Concurrent or previous have severe allergic reaction to any antibody-based drugs. 13. Existence of any concurrent autoimmune disease, excepting participants with diabetes mellitus type I, hypothyroidism requiring only hormone replacement therapy. 14. Receive live vaccines within 28 days before the first dose of study treatment or during the study period, excepting inactivated viral vaccines for seasonal influenza. 15. Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation. 16. Existence of systemic disease that is difficult to control despite treatment with several agents, for example, diabetes mellitus, hypertension, etc. 17. Existence of other serious physical or mental diseases or serious laboratory abnormalities that may increase the risk of participating in the study. Participants who were judged unsuitable as subjects of this trial by investigator.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
S1
S-1 orally intake as perioperative chemotherapy
Oxaliplatin
Oxaliplatin (130 mg/m2) infusion as perioperative chemotherapy
Serplulimab
Perioperative serplulimab, 300 mg IV infusion
Placebo
Perioperative placebo, 300 mg IV infusion

Locations

Country Name City State
China The First Affiliated Hospital, College of Medicine, Zhejiang University Hangzhou Zhejiang
China The Second Affiliated Hospital, College of Medicine, Zhejiang University Hangzhou Zhejiang
China Lishui Central Hospital Lishui Zhejiang
China Ningbo Medical Center LiHuiLi Hospital Ningbo Zhejiang
China Taizhou Hospital Taizhou Zhejiang

Sponsors (1)

Lead Sponsor Collaborator
Yu jiren

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of pathological complete responses (pCR) Percentage of patients with pCR referring to the total number of enrolled and eligible patients, as evaluated centrally by a reference pathologist. From enrollment to surgery after pre-operative treatment (up to approximately 36 months)
Secondary Overall survival Overall survival (OS) will be determined by measuring the time interval from enrollment to the end of follow up or death from any cause From enrollment to the end of follow up or death from any cause (up to approximately 60 months)
Secondary Progression-free survival Progression-free survival (PFS) will be defined as the time from enrollment to the end of follow up or the time of disease progression or relapse or death from any cause From enrollment to the end of follow up or the time of disease progression or relapse or death from any cause (up to approximately 60 months)
Secondary The incidences and types of adverse events (AE) and severe adverse events (SAE) The incidences and types of adverse events that occur during treatment will be evaluated according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 From enrollment to 90-day after the last dose administration (up to approximately 27 months)
See also
  Status Clinical Trial Phase
Completed NCT00982592 - Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer Phase 2
Recruiting NCT04077255 - EGFR-targeted Therapy for Gastric Cancer Phase 2
Terminated NCT01233505 - Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors Phase 1
Terminated NCT00098527 - FR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal Junction Cancer Phase 2
Active, not recruiting NCT03647969 - Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer Phase 2
Terminated NCT00871273 - Pharmacokinetic Study of Capecitabine After Total Gastrectomy for Stomach Adenocarcinoma Phase 4
Recruiting NCT05729646 - Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma Phase 2
Recruiting NCT06299163 - NM32-2668 in Adult Patients With Selected Advanced Solid Tumors Phase 1
Recruiting NCT05315830 - A Study of HER2 Tumor Vaccine in Patients With Her-2 Positive Gastric/GEJ Adenocarcinoma Esophagogastric Phase 1
Active, not recruiting NCT01095120 - Tesetaxel as Second-line Therapy for Patients With Advanced Gastric Cancer Phase 2
Completed NCT00062374 - Irinotecan and Cisplatin in Treating Patients Who Are Undergoing Surgery For Locally Advanced Cancer of the Stomach or Gastroesophageal Junction Phase 2
Not yet recruiting NCT05970627 - Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma Phase 2
Active, not recruiting NCT02202759 - A Study of MLN0264 in Patients With Cancer of the Stomach or Gastroesophageal Junction Phase 2
Recruiting NCT01962519 - Early Oral Feeding After Total Gastrectomy for Cancer N/A
Completed NCT00607594 - Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer Phase 2
Recruiting NCT06121700 - Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer Phase 2
Terminated NCT03722108 - Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal Adenocarcinomas Phase 1/Phase 2
Recruiting NCT05715931 - Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma Phase 2
Recruiting NCT02678182 - Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial Phase 2
Completed NCT01640782 - Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach Phase 3